Peptide Companion
Back to catalog
Peptide Companion
single
Weight Management
Vial: 10 mg

Survodutide (10 mg Vial)

Survodutide (BI 456906) is an investigational dual GLP‑1/glucagon receptor agonist under development for obesity and metabolic liver disease. In phase 2 trials, once‑weekly subcutaneous dosing (0.6–4.8 mg) produced dose‑dependent weight loss of 12.5–14.9% versus placebo over 46 weeks. This educational protocol presents a once‑weekly subcutaneous titration approach using a practical dilution for clear insulin‑syringe measurements.

Detailed protocol below.

Dosing Schedule
WeekWeekly Dose (mg)Weekly Dose (mcg)Units (mL)
Weeks 1–20.6 mg600 mcg12 units (0.12 mL)
Weeks 3–41.2 mg1200 mcg24 units (0.24 mL)
Weeks 5–61.8 mg1800 mcg36 units (0.36 mL)
Weeks 7–82.4 mg2400 mcg48 units (0.48 mL)
Weeks 9–103.6 mg3600 mcg72 units (0.72 mL)
Weeks 11–124.8 mg4800 mcg96 units (0.96 mL)
Week 13+6.0 mg6000 mcg120 units (1.20 mL)\*
Supplies Needed
  • •Peptide Vials (Survodutide, 10 mg each):
  • •Insulin Syringes (U‑100) or 1 mL Luer‑lock Syringes:
  • •Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
  • •Alcohol Swabs: One for the vial stopper + one for the injection site each week.
References

  • Lancet Diabetes & Endocrinology (2024)

    Le Roux et al. Phase 2 trial of once‑weekly SC survodutide (0.6–4.8 mg) in obesity; dose‑dependent weight loss of 12.5–14.9%

    View source

  • Journal of Hepatology (2023)

    Guo et al. Efficacy, tolerability, and pharmacokinetics of survodutide in NAFLD/NASH patients (cirrhosis cohort)

    View source

  • Obesity (Silver Spring) (2024)

    Wharton et al. SYNCHRONIZE‑1 & 2 phase 3 trial design for survodutide in obesity

    View source

  • JACC: Heart Failure (2024)

    Kosiborod et al. SYNCHRONIZE‑CVOT design: survodutide in patients at cardiovascular risk

    View source

  • Diabetology & Metabolic Syndrome (2024)

    Wan et al. Meta‑analysis of survodutide weight‑loss efficacy across randomized controlled trials

    View source

  • CDC

    Vaccine administration: subcutaneous route (angle/site guidance; no aspiration required)

    View source

  • CDC (Subcut Injection PDF)

    Technique diagram and site guidance for subcutaneous injections

    View source

  • MedlinePlus (NIH)

    Giving an insulin injection: patient guide for subcutaneous technique

    View source

  • Veterans Affairs (2023)

    Insulin injection: how to use and where to inject (injection sites, rotation guidance)

    View source

  • NCBI Bookshelf

    Best practices for injection (asepsis, preparation, and administration)

    View source

  • Subcutaneous Drug Injection Review (PMC)

    Pharmacologic considerations of the subcutaneous route

    View source

Educational content adapted from peptidedosages.com. Not medical advice.